Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at American Association for Cancer Research Virtual Annual Meeting 2020

On April 21, 2020 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported the presentation of the results for Cohort 1 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (Press release, Spectrum Pharmaceuticals, APR 21, 2020, View Source [SID1234556452]). The abstract titled "Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients – a Phase 2 study" will be part of the Lung Cancer Targeted Therapy session at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting I, to be held April 27-28, 2020. Full details of the presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Abstract Title: Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients – a Phase 2 study
Authors: Xiuning Le, M.D., Ph.D., et al.
Session: VCTPL08 – Lung Cancer Targeted Therapy
Date and Time: April 27, 2020, 2:05 p.m. – 2:15 p.m. EDT
Abstract Number: CT081
Location: The first edition of the AACR (Free AACR Whitepaper) Virtual Annual Meeting will be available free to everyone. Attendees will be asked to create an account to access the meeting platform which could be found at: View Source

Conference Call and Webcast

Spectrum’s management will host a webcast and conference call at 8:30 a.m. ET / 5:30 a.m. PT on April 28, 2020 to review the data and program strategy. The live call may be accessed by dialing (877) 837-3910 for domestic callers and (973) 796-5077 for international callers and entering the conference ID#: 5536065. A live webcast of the call will be available from the Investors and Media section of the company’s website at View Source and will be archived there shortly after the live event.